Evidence map›Paper›PMID 40278983›Full record

ArticleDiscover oncology2025

S100A7 as a predictive biomarker in malignant transformation of oral epithelial dysplastic lesions.

Jeffrey Soparlo, Lachlan McLean, Christina McCord, Linda Jackson-Boeters, Michael Shimizu, Michael Robinson, Wanninayake M Tilakaratne, Mark R Darling

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jeffrey SoparloUniversity of Western Ontario, London, ON, Canada.
Lachlan McLeanUniversity of Western Ontario, London, ON, Canada.
Christina McCordUniversity of Western Ontario, London, ON, Canada.
Linda Jackson-BoetersUniversity of Western Ontario, London, ON, Canada.
Michael ShimizuUniversity of Western Ontario, London, ON, Canada.
Michael RobinsonUniversity of Western Ontario, London, ON, Canada.
Wanninayake M TilakaratneFaculty of Dentistry, University of Malaya, Kuala, Lumpur, Malaysia.
Mark R DarlingDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, The University of Western Ontario, HSA 424, London, ON, N6A 5C1, Canada. mdarlin@uwo.ca.ORCID http://orcid.org/0000-0002-5404-2201

Funding

Canadian Association of Oral and Maxillofacial Surgeons R3586A09
6 · The paper itself

Abstract

backgroundS100A7 expression is increased in oral potentially malignant disorders (OPMD) at risk of transformation to oral squamous cell carcinoma (OSCC). The objective of this study was to evaluate S100A7 expression in OPMD which transformed and to correlate these results with the 3-tier and 2-tier dysplasia grading systems, and an S100A7 immunohistochemistry-based signature algorithm (S100A7 ARS).

methodsFormalin fixed paraffin embedded specimens from 48 patients with OPMD that had transformed into OSCC were selected. Thirty-five patients with multiple biopsies of dysplasia which had not transformed, and 25 cases with normal appearing and/or hyperkeratotic oral mucosa were included as control groups. Specimens were stained for S100A7 protein by immunohistochemical methods. Expression of S100A7 was assessed semi-quantitatively and by image analysis for the S100A7 ARS.

resultsThe semi-quantitative score had strong correlation with the S100A7 ARS and allowed differentiation of OPMD from the Control groups. The S100A7ARS was also useful in differentiation of OPMD that transformed to carcinoma from non-transforming cases (p < 0.05).

conclusionS100A7 immunohistochemical staining and the S100A7 ARS has potential for identifying oral potentially malignant lesions that have an increased risk of malignant transformation.

Indexed as

ImmunohistochemistryOral epithelial dysplasiaOral squamous cell carcinomaS100A7

Identifiers

PMID40278983
PMCPMC12031700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.